CryoPort (NASDAQ:CYRX) CEO Sells $429,408.00 in Stock

CryoPort, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 28,800 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total transaction of $429,408.00. Following the completion of the sale, the chief executive officer owned 1,201,814 shares of the company’s stock, valued at $17,919,046.74. The trade was a 2.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

CryoPort Trading Up 2.2%

Shares of NASDAQ CYRX opened at $15.13 on Friday. CryoPort, Inc. has a 1-year low of $7.61 and a 1-year high of $16.89. The company has a 50-day moving average of $15.39 and a two-hundred day moving average of $12.04. The company has a market cap of $766.33 million, a PE ratio of -16.81 and a beta of 1.89.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $48.97 million for the quarter, compared to the consensus estimate of $48.18 million. CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. As a group, equities research analysts forecast that CryoPort, Inc. will post -0.83 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on CYRX. BTIG Research lifted their target price on CryoPort from $17.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Guggenheim upped their price target on CryoPort from $12.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, August 7th. KeyCorp raised their price target on CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Craig Hallum lifted their price objective on CryoPort from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, June 3rd. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of CryoPort in a report on Monday, August 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, CryoPort has an average rating of “Moderate Buy” and an average price target of $18.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. LPL Financial LLC boosted its position in shares of CryoPort by 6.6% in the 4th quarter. LPL Financial LLC now owns 23,306 shares of the company’s stock worth $224,000 after purchasing an additional 1,433 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in CryoPort by 9.4% in the second quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock valued at $136,000 after buying an additional 1,557 shares during the period. State of Wyoming boosted its holdings in CryoPort by 30.2% during the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock worth $106,000 after buying an additional 3,301 shares during the last quarter. Basepoint Wealth LLC acquired a new position in shares of CryoPort during the 4th quarter worth about $34,000. Finally, BNP Paribas Financial Markets increased its stake in shares of CryoPort by 55.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company’s stock valued at $113,000 after acquiring an additional 4,225 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.